PMID- 34469617
OWN - NLM
STAT- MEDLINE
DCOM- 20220325
LR  - 20220325
IS  - 1098-1101 (Electronic)
IS  - 0733-2459 (Linking)
VI  - 36
IP  - 6
DP  - 2021 Dec
TI  - Therapeutic plasma exchange for life-threatening pediatric disorders.
PG  - 823-830
LID - 10.1002/jca.21934 [doi]
AB  - INTRODUCTION: Therapeutic plasma exchange (TPE) is acknowledged to be an 
      effective treatment in life-threatening pediatric disorders. Apheresis for 
      pediatric diseases has been poorly investigated, and most studies to date 
      featured small numbers of patients and lacked control groups. The objective of 
      the present study was to evaluate the tolerance of TPE in pediatric patients. 
      MATERIALS AND METHODS: A retrospective cohort study via a web-based electronic 
      case report form including pediatric patients referred for TPE between January 
      2005 and December 2014. RESULTS: A total of 78 patients (median [range] age: 9.8 
      [0.53-17.93]) and 731 TPE procedures were analyzed. The indications were 
      antibody-mediated rejection (n = 33; 42%) and desensitization therapy (n = 5; 6%) 
      after solid organ or hematopoietic stem cell transplantation, thrombotic 
      microangiopathy (n = 17; 22%), pediatric inflammatory diseases (n = 16; 21%), 
      kidney diseases (n = 6; 8%), and hyperviscosity syndrome (n = 1; 1%). On average, 
      each patient underwent six procedures during the first session [range: 1-19]. In 
      the 2 weeks following the start of a session, 72 patients (92%) presented a total 
      of 311 adverse events (AEs) potentially related to TPE. The risk of AEs was not 
      related to the indication for TPE, the intensity of care, venous access, plasma 
      substitute use, or body weight. None of the deaths was related to the TPE. 
      CONCLUSION: We studied one of the largest retrospective pediatric cohorts 
      described to date. Our experience of TPE children's TPE feasibility concerned 
      specific, life-threatening conditions and otherwise treatment-refractory 
      diseases.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Diana, Jean-Sebastien
AU  - Diana JS
AUID- ORCID: 0000-0001-8806-011X
AD  - Hopital Necker Enfants Malades, Paris, France.
AD  - Universite de Paris, Paris, France.
FAU - Manceau, Sandra
AU  - Manceau S
AD  - Hopital Necker Enfants Malades, Paris, France.
AD  - Universite de Paris, Paris, France.
FAU - Rabeony, Tioka
AU  - Rabeony T
AD  - Institut Imagine, Paris, France.
FAU - Elie, Caroline
AU  - Elie C
AD  - Universite de Paris, Paris, France.
AD  - Institut Imagine, Paris, France.
FAU - Jolaine, Valerie
AU  - Jolaine V
AD  - Universite de Paris, Paris, France.
AD  - Institut Imagine, Paris, France.
FAU - Zamora, Sandrine
AU  - Zamora S
AD  - Hopital Necker Enfants Malades, Paris, France.
FAU - Aubart, Melodie
AU  - Aubart M
AD  - Hopital Necker Enfants Malades, Paris, France.
FAU - Salvi, Nadege
AU  - Salvi N
AD  - Hopital Necker Enfants Malades, Paris, France.
FAU - Bodemer, Christine
AU  - Bodemer C
AD  - Hopital Necker Enfants Malades, Paris, France.
AD  - Universite de Paris, Paris, France.
FAU - Bader-Meunier, Brigitte
AU  - Bader-Meunier B
AD  - Hopital Necker Enfants Malades, Paris, France.
FAU - Barnerias, Christine
AU  - Barnerias C
AD  - Hopital Necker Enfants Malades, Paris, France.
FAU - Iserin, Franck
AU  - Iserin F
AD  - Hopital Necker Enfants Malades, Paris, France.
FAU - Chardot, Christophe
AU  - Chardot C
AD  - Hopital Necker Enfants Malades, Paris, France.
AD  - Universite de Paris, Paris, France.
FAU - Lacaille, Florence
AU  - Lacaille F
AD  - Hopital Necker Enfants Malades, Paris, France.
FAU - Renolleau, Sylvain
AU  - Renolleau S
AD  - Hopital Necker Enfants Malades, Paris, France.
AD  - Universite de Paris, Paris, France.
FAU - Salomon, Remi
AU  - Salomon R
AD  - Hopital Necker Enfants Malades, Paris, France.
AD  - Universite de Paris, Paris, France.
FAU - Joseph, Laure
AU  - Joseph L
AD  - Hopital Necker Enfants Malades, Paris, France.
FAU - Cavazzana, Marina
AU  - Cavazzana M
AD  - Hopital Necker Enfants Malades, Paris, France.
AD  - Universite de Paris, Paris, France.
AD  - Institut Imagine, Paris, France.
FAU - Lefrere, Francois
AU  - Lefrere F
AD  - Hopital Necker Enfants Malades, Paris, France.
FAU - Dupic, Laurent
AU  - Dupic L
AD  - Hopital Necker Enfants Malades, Paris, France.
FAU - Delville, Marianne
AU  - Delville M
AD  - Hopital Necker Enfants Malades, Paris, France.
AD  - Universite de Paris, Paris, France.
AD  - Institut Imagine, Paris, France.
LA  - eng
GR  - The << Assistance Publique des Hopitaux de Paris >> supports this project./
PT  - Journal Article
DEP - 20210901
PL  - United States
TA  - J Clin Apher
JT  - Journal of clinical apheresis
JID - 8216305
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Critical Care/*methods
MH  - Feasibility Studies
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Inflammation/therapy
MH  - Intensive Care Units, Pediatric
MH  - Kidney Diseases/therapy
MH  - Male
MH  - Plasma Exchange/adverse effects/*methods
MH  - Retrospective Studies
MH  - Thrombotic Microangiopathies/therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - adverse event
OT  - eCRF database
OT  - pediatric intensive care unit
EDAT- 2021/09/02 06:00
MHDA- 2022/03/26 06:00
CRDT- 2021/09/01 17:28
PHST- 2021/07/12 00:00 [revised]
PHST- 2020/08/27 00:00 [received]
PHST- 2021/08/17 00:00 [accepted]
PHST- 2021/09/02 06:00 [pubmed]
PHST- 2022/03/26 06:00 [medline]
PHST- 2021/09/01 17:28 [entrez]
AID - 10.1002/jca.21934 [doi]
PST - ppublish
SO  - J Clin Apher. 2021 Dec;36(6):823-830. doi: 10.1002/jca.21934. Epub 2021 Sep 1.